Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WTX-330 |
Synonyms | |
Therapy Description |
WTX-330 comprises IL-12 linked to an antibody blockade domain and a half-life extension domain by linkers that can be cleaved by proteases in the tumor microenvironment, which potentially enhances antitumor immune response and reduces tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2055). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WTX-330 | WTX 330|WTX330 | WTX-330 comprises IL-12 linked to an antibody blockade domain and a half-life extension domain by linkers that can be cleaved by proteases in the tumor microenvironment, which potentially enhances antitumor immune response and reduces tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2055). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05678998 | Phase I | WTX-330 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | Completed | USA | 0 |